Effects of modafinil
on
symptomatology of human narcolepsy.
Caldwell JA, Caldwell JL, Smythe NK, Hall KK
Centre d'etude du sommeil,
Hopital du Sacre-Coeur, Montreal, Quebec, Canada.
Clin Neuropharmacol 1993 Feb;16(1):46-53
ABSTRACT
We studied the effects of
modafinil, a putative central alpha-1 agonist, on the excessive daytime
sleepiness (EDS) of 10 narcoleptic patients while using a double-blind design
and objective measurements of vigilance. There were two treatment periods, in
which either modafinil or placebo was used; each lasted four weeks and was
preceded by a 2-week "run-in" period and separated by a 2-week
"wash-out" period. The effects of treatment on EDS were evaluated by
daily home questionnaires and a psychomotor performance test, the Four Choice
Reaction Time Test (FCRTT). Modafinil reduced the daily number of
sleep attacks significantly, and markedly improved performances
during the FCRTT. Results of this study suggest that modafinil is effective in
treating EDS in narcolepsy, and that noradrenergic mechanisms could be
involved in the physiopathology of EDS in that disorder.
1. Modafinil for
sustaining the alertness of helicopter pilots
2. Modafinil augmentation
of antidepressant treatment
3. Modafinil the
unique properties of a new stimulant
4. Modafinil children
with attention-deficit/hyperactivity disorder
5. Modafinil dosage
and safety
6. Modafinil successful
treatment of hypersomnia & narcolepsy
7. Modafinil narcolepsy:
symptoms and management
8. Modafinil
amplification of cortical serotonin release
9. Modafinil
treatment of alcoholic organic brain syndrome
10. Modafinil
effect on melatonin, cortisol, and growth hormone
11. Modafinil
in obstructive sleep apnea-hypopnea syndrome
12. Modafinil
vs dextroamphetamine in treatment of adult ADHD
13. Modafinil
efficacy in narcolepsy
14. Modafinil
switching from narcolepsy drugs to modafinil
15. Modafinil
dopaminergic transmission mediates CNS stimulants
